SCHEMBL385940

SCHEMBL385940

CC(N)(CCc1ccc(C#CCOc2ccc(C(F)(F)F)cc2)o1)CCP(=O)(O)O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR4 O95977 3/20 0.43
S1PR1 P21453 3/20 0.43
S1PR3 Q99500 3/20 0.43
S1PR5 Q9H228 3/20 0.43
ALDH1A1 P00352 1/20 0.35
EGLN1 Q9GZT9 2/20 0.35
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
PTPRC P08575 1/20 0.31
PTPN2 P17706 1/20 0.31
PTPN1 P18031 1/20 0.31
PTPRB P23467 1/20 0.31
PTPN6 P29350 1/20 0.31
CDC25A P30304 1/20 0.31
PTPN11 Q06124 1/20 0.31
TRPM8 Q7Z2W7 1/20 0.31
PPARA Q07869 2/20 0.31
MAOB P27338 1/20 0.31
AOC3 Q16853 1/20 0.31
MDH1 P40925 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL387349 0.90 S1PR1 (0.45) S1PR4S1PR1S1PR3S1PR5EGLN1
SCHEMBL387299 0.89 KDM4E (0.39) S1PR4S1PR1S1PR3S1PR5EGLN1
SCHEMBL385562 0.89 S1PR1 (0.45) S1PR4S1PR1S1PR3S1PR5ALDH1A1
SCHEMBL385516 0.88 S1PR1 (0.44) S1PR4S1PR1S1PR3S1PR5ALDH1A1
SCHEMBL385512 0.86 ALDH1A1 (0.34) ALDH1A1EGLN1NPC1RAB9ATRPM8
SCHEMBL383973 0.85 S1PR4 (0.41) S1PR4S1PR1S1PR3S1PR5ALDH1A1
SCHEMBL386197 0.84 S1PR4 (0.40) S1PR4S1PR1S1PR3S1PR5NPC1
SCHEMBL385953 0.78 EGLN1 (0.40) S1PR4S1PR1S1PR3S1PR5EGLN1
SCHEMBL386328 0.78 ACP3 (0.39) S1PR4S1PR1S1PR3S1PR5NPC1
SCHEMBL384321 0.77 S1PR1 (0.46) S1PR4S1PR1S1PR3S1PR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101650-B2 Method for treating a immunology-related disease DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-01-24 US disclosed
US-8067396-B2 Amino alcohol compounds or phosphonic acid derivatives thereof SANKYO COMPANY, LIMITED (JP) 2011-11-29 US disclosed
US-20100035842-A1 Amino alcohol compounds or phosphonic acid derivatives thereof SANKYO COMPANY, LIMITED (JP) 2010-02-11 US disclosed
US-20090326038-A1 Method for treating a immunology-related disease SANKYO COMPANY, LIMITED (JP) 2009-12-31 US disclosed
US-7638551-B2 Amino alcohol compounds or phosphonic acid derivatives thereof SANKYO COMPANY, LIMITED (JP) 2009-12-29 US disclosed
EP-1471054-B1 AMINO ALCOHOL DERIVATIVE OR PHOSPHONIC ACID DERIVATIVE AND MEDICINAL COMPOSITION CONTAINING THESE DAIICHI SANKYO CO LTD (JP) 2009-07-01 EP disclosed
US-20070142335-A1 Amino alcohol compounds or phosphonic acid derivatives thereof SANKYO COMPANY, LIMITED (JP) 2007-06-21 US disclosed
US-20070105933-A1 Amino alcohol compounds SANKYO COMPANY, LIMITED (JP) 2007-05-10 US disclosed
US-7199150-B2 Amino alcohol compounds SANKYO COMPANY, LIMITED (JP) 2007-04-03 US disclosed
US-20050043386-A1 Amino alcohol derivatives or phosphonic acid derivatives and pharmaceutical compositions containing these SANKYO COMPANY, LIMITED (JP) 2005-02-24 US disclosed
EP-1471054-A1 AMINO ALCOHOL DERIVATIVE OR PHOSPHONIC ACID DERIVATIVE AND MEDICINAL COMPOSITION CONTAINING THESE Sankyo Company, Limited (JP) 2004-10-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043386-A1 Amino alcohol derivatives or phosphonic acid derivatives and pharmaceutical compositions containing these PHOSPHO1, CD4, FCGRT S1PR4 1110/4885S1PR1 257/4885S1PR3 414/4885
US-20090326038-A1 Method for treating a immunology-related disease C3AR1, HRH3, HRH2 S1PR4 519/4885S1PR1 159/4885S1PR3 194/4885
US-20070105933-A1 Amino alcohol compounds ADH1C, C9, SSB S1PR4 1344/4885S1PR1 465/4885S1PR3 504/4885
US-20070142335-A1 Amino alcohol compounds or phosphonic acid derivatives thereof HRH3, C3AR1, HRH4 S1PR4 281/4885S1PR1 70/4885S1PR3 89/4885
US-20100035842-A1 Amino alcohol compounds or phosphonic acid derivatives thereof PHOSPHO1, ADH1C, ADH1A S1PR4 1542/4885S1PR1 593/4885S1PR3 622/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.